Complement fragments are biomarkers of antibody-mediated endothelial injury
Introduction
Kidney transplantation is the optimal treatment for patients with end stage renal disease (ESRD) (Wolfe et al., 1999). However, acute and/or chronic immunologic injury mediated by donor-specific antibodies (DSAs) against donor human leukocyte antigens (HLA) is a major cause of kidney graft loss and is a significant barrier to long-term graft survival (Sellares et al., 2012). AbMR is characterized pathologically by microvascular injury and inflammation. Even in the absence of graft dysfunction, these pathologic changes on surveillance biopsies (subclinical AbMR) are associated with inferior graft outcomes (Loupy et al., 2015; Orandi et al., 2015). The diagnosis of AbMR also requires evidence of DSA interaction with the endothelium, usually detected as C4d deposition in the peritubular capillaries (Haas, 2014). During antibody-mediated classical pathway activation C4 is covalently attached to target tissues, providing a durable marker of this process. Although there are cases of C4d-negative AbMR, complement activation is associated with a poorer prognosis and is generally considered an important contributor to graft injury in AbMR (Feucht et al., 1993; Kikic et al., 2015).
Because of the impact of AbMR, with or without concurrent graft dysfunction, on short- and long-term graft outcomes, better methods for diagnosing and monitoring its presence are needed. Currently, a kidney biopsy is required for diagnosis of AbMR, and the only tools available for surveillance are protocol biopsy and serially monitoring for DSA. While DSA monitoring is an attractive option because it is noninvasive and widely available, it has low specificity for subclinical AbMR and frequently does not reflect active inflammation and injury (Parajuli et al., 2017; Schinstock et al., 2017). In addition to a potential pathogenic role in allograft injury, complement activation also generates several soluble fragments that can serve as clinical biomarkers of inflammation (Frazer-Abel et al., 2016). For example, every molecule of C4b that is attached to target cells is accompanied by release of a C4a fragment. Classical pathway activation within the allograft may, therefore, increase C4a levels in the plasma.
Damaged endothelial cells also release microvesicles. Microvesicles are sub-micrometer-sized membrane-bound vesicles (0.05−1 μm) shed from a variety of cells, including endothelial cells, both constitutively and in response to activation, injury, and apoptosis (Anderson et al., 2010; Beyer and Pisetsky, 2010). Studies have demonstrated that endothelial microvesicles increase in diseases associated with endothelial injury, and they can be isolated from peripheral blood as circulating markers of events at the cellular level (Boulanger et al., 2007; Chironi et al., 2009; Hsu et al., 2013). It was also reported that AbMR increases the number of C4-opsonized endothelial microvesicles, possibly reflecting complement-mediated endothelial injury (Tower et al., 2016).
We hypothesized that antibody-mediated complement activation would lead to increased generation of soluble complement activation fragments and release of C3 or C4-bearing endothelial microvesicles that could serve as plasma-derived biomarkers of AbMR in renal transplant recipients. To test this hypothesis, we developed and characterized an in vitro model of AbMR using immortalized human endothelial cells and collected pilot data with samples from renal transplant recipients with impaired graft function in the absence of AbMR and from patients with biopsy-proven AbMR.
Section snippets
Complement activation, deposition, and clearance on endothelial cells
Confluent HMEC-1 cells grown in 6-well plates were incubated with a saturating concentration of mAb W6/32 (3 μg/mL) for 30 min at 37 °C (see Supplementary Fig. 1). Cells were subsequently washed with PBS and incubated with culture medium with or without 10 % normal human serum (NHS; Quidel, San Diego, CA) at 37 °C. Higher NHS concentrations were examined but did not significantly alter the results using this model. The degree of C4 deposition per cell was greater when subconfluent cells were
Complement activation on endothelial cells in culture
HMEC-1 cells were incubated with a saturating concentration of anti-HLA class I antibody (W6/32) (Supplemental Fig. 1) and subsequently exposed to NHS to elicit complement activation and deposition on the cell surface (Fig. 1). Early after serum exposure, active C4 in the form of C4b (recognized by an anti-C4c detection antibody) is abundant but subsequently declines at later time points (Fig. 1A). This decline is presumably due to conversion to the inactive form C4d that is detected early
Discussion
In this study we developed an in vitro model of AbMR using immortalized human microvascular endothelial cells and a monoclonal anti-class I HLA antibody to test whether complement activation fragments and endothelial microvesicles could serve as biomarkers of AbMR. Our model approximates the pathophysiology of AbMR in transplant recipients as demonstrated by the deposition of complement fragments on the cell surface, analogous to C4d fixation on endothelial cells in transplant biopsies with
Conclusion
Our in vitro model and pilot clinical data show that soluble complement fragments generated by antibody-mediated complement activation on the endothelium can be detected and give insight to events at the cellular level. Our data also suggests that circulating microvesicles are not a reliable biomarker of AbMR in contrast to a previous report. Current methods for surveillance and diagnosis of AbMR rely on detection of DSA and analysis of various antibody characteristics (i.e. titer, sub-class,
Authors’ contributions
JT, ES and ML designed research. ES, JL, BR, ML performed experiments. ZY, BF, JC, and DL helped analyze the results. ES and JT wrote the manuscript, and all authors critically read and commented on manuscript drafts.
Conflict of interest
JMT receives royalties from Alexion Pharmaceuticals, Inc., and is a consultant for AdMIRx, Inc., a company developing complement inhibitors. He also holds stock and will receive royalty income from AdMIRx.
CRediT authorship contribution statement
Erik Stites: Conceptualization, Investigation, Writing - original draft. Brandon Renner: Methodology, Investigation. Jennifer Laskowski: Methodology, Investigation. Moglie Le Quintrec: Conceptualization, Investigation, Resources. Zhiying You: Formal analysis. Brian Freed: Resources. James Cooper: Resources. Diana Jalal: Conceptualization, Resources. Joshua M. Thurman: Conceptualization, Methodology, Writing - review & editing, Funding acquisition.
Acknowledgements
This work was supported by National Institutes of HealthT32 DK007135 (ES), DK113586 and DK076690 (JMT). Imaging experiments were performed in the University of Colorado Anschutz Medical Campus Advance Light Microscopy Core supported in part by NIH/NCATS Colorado CTSI Grant Number UL1 TR001082. We would like to acknowledge the assistance of the University of Colorado Flow Cytometry Shared Resource, as well as Ronald P. Taylor and Margaret A. Lindorfer who generously provided the 3E7 and 1H8
References (35)
- et al.
Role of extracellular membrane vesicles in the pathogenesis of various diseases, including cancer, renal diseases, atherosclerosis, and arthritis
Lab. Investig.
(2010) - et al.
Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b
Mol. Immunol.
(2006) - et al.
Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial
Am. J. Transplant.
(2018) - et al.
Capillary deposition of C4d complement fragment and early renal graft loss
Kidney Int.
(1993) - et al.
Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation
Adv. Clin. Chem.
(2016) - et al.
The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
Am. J. Transplant.
(2018) - et al.
C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings
Am. J. Transplant.
(2006) - et al.
C4d deposition and clearance in cardiac transplants correlates with alloantibody levels and rejection in rats
Am. J. Transplant.
(2006) - et al.
Live cell imaging of outward and inward vesiculation induced by the complement C5b-9 complex
J. Biol. Chem.
(2007) - et al.
Quantifying renal allograft loss following early antibody-mediated rejection
Am. J. Transplant.
(2015)
Utility of protocol kidney biopsies for de novo donor-specific antibodies
Am. J. Transplant.
Antibody-mediated rejection criteria – an addition to the Banff 97 classification of renal allograft rejection
Am. J. Transplant.
The value of protocol biopsies to identify patients with de novo donor-specific antibody at high risk for allograft loss
Am. J. Transplant.
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence
Am. J. Transplant.
A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice
Mol. Immunol.
The role of microparticles in the pathogenesis of rheumatic diseases. Nature reviews
Rheumatology
In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease
Hypertension
Cited by (10)
Circular RNAs: Regulators of endothelial cell dysfunction in atherosclerosis
2024, Journal of Molecular MedicineEffects of different freezing techniques on the rejection of allogeneic vascular transplantation
2024, Chinese Journal of Tissue Engineering ResearchTargeting the Complement Pathway in Kidney Transplantation
2023, Journal of the American Society of NephrologyThe complement system in pediatric acute kidney injury
2023, Pediatric NephrologyThe susceptibility of the kidney to alternative pathway activation—A hypothesis
2023, Immunological ReviewsExtracellular vesicles derived from patients with antibody-mediated rejection induce tubular senescence and endothelial to mesenchymal transition in renal cells
2022, American Journal of Transplantation